(Q37177507)

18 August 2017

1 reference

title

Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment (English)

1 reference

18 August 2017

0 references

irritable bowel syndrome

1 reference

Gareth C Parkes

1

1 reference

18 August 2017

Jonathan Brostoff

series ordinal

2

1 reference

18 August 2017

Kevin Whelan

series ordinal

3

1 reference

18 August 2017

Jeremy D Sanderson

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

29 May 2008

1 reference

The American Journal of Gastroenterology

18 August 2017

published in

1 reference

18 August 2017

volume

103

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

1557-1567

1 reference

Functional bowel disorders

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The impact of irritable bowel syndrome on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Applied principles of neurogastroenterology: physiology/motility sensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Intestinal microecology and quality of life in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The intestinal epithelial barrier: how to distinguish between the microbial flora and pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Comparative study of the intestinal mucus barrier in normal and inflamed colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Modulation of human dendritic cell phenotype and function by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Abnormal colonic fermentation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Origin of gas retention and symptoms in patients with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Inflammatory bowel disease and irritable bowel syndrome: separate or unified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Activated innate immune system in irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The effects of antibiotic use on gastrointestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Small bowel bacterial overgrowth in subjects living in residential care homes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Probiotics--snake oil for the new millennium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Probiotic bacteria enhance murine and human intestinal epithelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01869.X

10.1111/J.1572-0241.2008.01869.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference